HERG1 promotes esophageal squamous cell carcinoma growth and metastasis through TXNDC5 by activating the PI3K/AKT pathway

• Published in: Journal of experimental & clinical cancer research Vol. 38; no. 1; p. 324
• Main Authors: Wang, Hongqiang, Yang, Xuchun, Guo, Yan, Shui, Lin, Li, Shi, Bai, Yifeng, Liu, Yu, Zeng, Ming, Xia, Jianling
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 22.07.2019; BioMed Central; BMC
• Subjects: Aged; Animals; Apoptosis - genetics; Biomarkers, Tumor - genetics; Cancer; Cell Line, Tumor; Cell Movement - genetics; Cell Proliferation - genetics; Chemotherapy; Diagnosis; Disease-Free Survival; Epithelial-Mesenchymal Transition; Esophageal cancer; Esophageal squamous cell carcinoma; Esophageal Squamous Cell Carcinoma - genetics; Esophageal Squamous Cell Carcinoma - pathology; Ether-A-Go-Go Potassium Channels - genetics; Female; Gene Expression Regulation, Neoplastic - genetics; HERG1; Humans; Male; Mice; Middle Aged; Neoplasm Invasiveness - genetics; Neoplasm Invasiveness - pathology; Neoplasm Metastasis; Oncogene Protein v-akt - genetics; Phosphatidylinositol 3-Kinases - genetics; Prognosis; Protein Disulfide-Isomerases - genetics; Risk factors; Signal Transduction - genetics; Stem cells; Tumor progression; TXNDC5; Xenograft Model Antitumor Assays; China; HERG1; Esophageal squamous cell carcinoma; Tumor progression; TXNDC5
• ISSN: 1756-9966; 0392-9078; 1756-9966
• DOI: 10.1186/s13046-019-1284-y

The human ether a-go-go-related gene 1 (HERG1) is involved in tumor progression; however, its role in esophageal squamous cell carcinoma (ESCC) is not well studied. This study investigated HERG1 function in ESCC progression and elucidated the underlying mechanisms. The prognostic value of HERG1 was determined by immunohistochemistry in ESCC biopsies. Cell growth and proliferation were analyzed by colony formation and methyl thiazolyl tetrazolium assays. Cell migration and invasion were analyzed by wound healing and Boyden transwell assays. Epithelial-mesenchymal transition (EMT) was evaluated by immunoblotting and quantitative polymerase chain reaction (qPCR). A xenograft mouse model was used to validate the tumorigenic and metastatic roles of HERG1 in vivo. HERG1 expression was overall higher in ESCC tissues compared to adjacent non-tumor tissues. A retrospective analysis of 349 patients with ESCC (stages I-IV) confirmed increased HERG1 expression was associated with disease progression and higher mortality rate. The overall survival of the patients was significantly worse when their tumors displayed higher HERG1 expression. HERG1 knockdown reduced tumor growth and metastasis in athymic mice. HERG1 affected the proliferation, migration, and invasion of two ESCC cell lines (TE-1 and KYSE-30). Changes in HERG1 expression affected the expression of cell cycle- and EMT-related proteins; these effects were reversed by altering the expression of thioredoxin domain-containing protein 5 (TXNDC5), which is also associated with the clinicopathological characteristics of patients with ESCC and is relevant to HERG1 in pathological biopsies. Additionally, HERG1 expression altered phosphoinositide 3-kinase (PI3K) and AKT phosphorylation, thereby affecting TXNDC5 expression. HERG1 contributes to poor prognosis in patients with ESCC by promoting ESCC cell proliferation, migration, and invasion via TXNDC5 through the PI3K/AKT signaling pathway. Our findings provided novel insights into the pathology of ESCC and role of HERG1 in tumor progression, suggesting that targeting HERG1 has potential diagnostic and therapeutic value for ESCC treatment.